2022
The metabotropic glutamate receptor 5 as a biomarker for psychiatric disorders
Asch R, Hillmer A, Baldassarri S, Esterlis I. The metabotropic glutamate receptor 5 as a biomarker for psychiatric disorders. International Review Of Neurobiology 2022, 168: 265-310. PMID: 36868631, DOI: 10.1016/bs.irn.2022.10.007.Peer-Reviewed Original ResearchConceptsPsychiatric disordersMetabotropic glutamate receptor 5Positron emission tomography studyGlutamate receptor 5Utility of PETEmission tomography studiesPromising therapeutic targetStress-related disordersNumerous psychiatric disordersTreatment trialsGlutamate neurotransmissionGlutamate systemMGlu5 expressionSubtype 5Treatment responseMood disordersRole of mGlu5Receptor 5Therapeutic targetPsychiatric conditionsMGlu5Tomography studySubstance useTrauma disordersDisorders
2021
Risk and resilience factors associated with traumatic loss-related PTSD in U.S. military veterans: Results from the National Health and Resilience in Veterans Study
Asch RH, Esterlis I, Southwick SM, Pietrzak RH. Risk and resilience factors associated with traumatic loss-related PTSD in U.S. military veterans: Results from the National Health and Resilience in Veterans Study. Psychiatry Research 2021, 298: 113775. PMID: 33578060, DOI: 10.1016/j.psychres.2021.113775.Peer-Reviewed Original ResearchConceptsPosttraumatic stress disorderU.S. military veteransAttachment styleResilience factorsMilitary veteransPTSD symptom severitySomatic symptomsTraumatic eventsStress disorderPsychosocial correlatesPositive screenVeterans StudyNational HealthSudden deathSymptom severityTherapeutic targetU.S. veteransStrongest correlate